An Open-label, Multi-center Phase I Clinical Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of SHR-9539 Injection in Patients With Multiple Myeloma
Latest Information Update: 13 Aug 2024
At a glance
- Drugs SHR 9539 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Suzhou Suncadia Biopharmaceuticals
Most Recent Events
- 09 Aug 2024 Status changed from not yet recruiting to recruiting.
- 18 Jul 2024 According to a Hengrui Medicines media release, company received the "Drug Clinical Trial Approval Notice" approved and issued by the National Medical Products Administration, approving the Class 1 new drug SHR-9539 Injection to conduct clinical trials for multiple myeloma.
- 17 Jul 2024 New trial record